NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN...Warrant Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS CERTIFIES THAT, for value received, General Electric Capital Corporation (“Holder”) is entitled to subscribe for and purchase One Thousand Five Hundred Twenty Four (1,524) shares of the fully paid and nonassessable Series C Preferred Stock (the “Shares” or the “Preferred Stock”) of Sunesis Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term “Series C Preferred Stock” shall mean the Company’s presently authorized Series C Preferred Stock and any stock into which such Series C Preferred Stock may hereafter be converted or exchanged.
MASTER SERVICES AGREEMENT (“MSA”)Master Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
FIRST AMENDMENT TO THE MASTER SERVICES AGREEMENTMaster Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT (“Amendment”), effective September 11, 2006 (the “Amendment Effective Date”) is to the existing Master Services Agreement between AAIPharma Inc. (formerly AAI Development Services Inc., a division of AAIPharma Inc.) (hereinafter “AAIPharma”) and Sunesis Pharmaceuticals, Inc. (hereinafter the “Client”) dated November 3, 2003 (the “Agreement”). All capitalized terms herein shall have the same meaning as set forth in the Agreement.
MASTER SERVICES AGREEMENTMaster Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Master Services Agreement (“Agreement”) is made and entered into as of January 1, 2010 (the “Effective Date”), by and between Albany Molecular Research, Inc., having its principal place of business at 26 Corporate Circle, Albany, New York 12203 (together with its subsidiaries hereinafter collectively referred to as “AMRI”) and Sunesis Pharmaceuticals, Inc., having its principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (hereinafter “SUNESIS”). AMRI and SUNESIS are referred to individually as a “Party” and together as the “Parties” throughout this Agreement.
THIRD AMENDMENT TO THE MASTER SERVICES AGREEMENTMaster Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT (“Third Amendment”), effective as of November 3, 2009 (the “Amendment Effective Date”) is to the existing Master Services Agreement between AAIPharma Services Corp. (assignee of AAIPharma Inc. and hereinafter referred to as “AAIPharma”) and Sunesis Pharmaceuticals, Inc. (hereinafter the “Client”) dated November 3, 2003 (the “Agreement”), as amended September 11, 2006 and May 2, 2008 (respectively, the “First Amendment” and “Second Amendment”). All capitalized terms herein shall have the same meaning as set forth in the Agreement.
MASTER SERVICES AGREEMENTMaster Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Master Services Agreement (“Agreement’) is entered into as of November 3, 2003 (the “Effective Date”) by and between Sunesis Pharmaceuticals Incorporated, a Delaware corporation with an office at 341 Oyster Point Boulevard, South San Francisco, California 94080 (hereinafter the “Client”) and AAI Developmental Services Inc. with an office at 2320 Scientific Park Drive, Wilmington, NC 28405 (hereinafter “AAI”). The Client and AAI are referred to singly as “Party” and jointly as “Parties” throughout this Agreement.
SECOND AMENDMENT TO THE MASTER SERVICES AGREEMENTMaster Services Agreement • March 29th, 2011 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT (“Amendment”), effective May 2, 2008 (the “Amendment Effective Date”) is to the existing Master Services Agreement between AAIPharma Inc. (formerly AAI Development Services Inc., a division of AAIPharma Inc.) (hereinafter “AAIPharma”) and Sunesis Pharmaceuticals, Inc. (hereinafter the “Client”) dated November 3, 2003 and amended September 11, 2006 (the “Agreement”). All capitalized terms herein shall have the same meaning as set forth in the Agreement.
